Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Twitter Guidance Lacks Flexibility, And May Be Unconstitutional, Critics Say

This article was originally published in The Gray Sheet

Executive Summary

Stakeholders say the agency’s communication requirements for space-limited online platforms are too restricting and violate the First Amendment. Many of them are calling on the agency to withdraw the guidance and try again. The device industry has a comparatively toned down response so far, but wants more flexibility.

You may also be interested in...



YouTube Videos: Opportunities And Risks For Device Firms

Device-makers that have been reluctant to add product videos to YouTube might need to produce them anyway to counteract inaccurate or even dangerous user videos, one consultant says – but the step isn’t totally without risk. For example, attorney Colleen Heisey questions whether creating online video is the best use of a company’s limited resources: “You have to go viral to have the impact of millions of viewers … so you’re coming up with a digital engagement strategy, and the effort to do that might be better placed elsewhere."

CDRH Sets Date To Examine Patient-Focused Device Labeling Policies

The device center will convene a meeting at FDA headquarters in September to discuss all facets of device patient labeling.

Will #Cures2015 Fix Twitter Promotion?

House 21st Century Cures discussion draft would adjust FDA promotion regulations for Twitter, requiring that information communicated through hyperlink be considered part of the original post.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel